Ocugen Inc
OCGN1.330USD
0.0000.00%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
415.39MMarket Cap
LossP/E TTM
More Details of Ocugen Inc Company
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. Its technology pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, and Inhaled Mucosal Vaccine Platform. It is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal diseases, including retinitis pigmentosa, Leber congenital amaurosis, Stargardt disease and multifactorial diseases, such as dry age-related macular degeneration (dAMD) and geographic atrophy. It is developing a next-generation, inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine, and OCU520, a combination quadrivalent seasonal flu.
Ocugen Inc Info
Ticker SymbolOCGN
Company nameOcugen Inc
IPO dateDec 03, 2014
CEOMusunuri (Shankar)
Number of employees95
Security typeOrdinary Share
Fiscal year-endDec 03
Address11 Great Valley Parkway
CityMALVERN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code19355
Phone14843284701
Websitehttps://ocugen.com/
Ticker SymbolOCGN
IPO dateDec 03, 2014
CEOMusunuri (Shankar)
Company Executives of Ocugen Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Junge Zhang, Ph.D.
Mr. Junge Zhang, Ph.D.
Independent Director
Independent Director
1.17M
+117.00%
Dr. Arun Upadhyay, Ph.D.
Dr. Arun Upadhyay, Ph.D.
Chief Scientific Officer, Head of Research and Development
Chief Scientific Officer, Head of Research and Development
214.50K
+153362.00%
Mr. Ramesh Ramachandran, CPA
Mr. Ramesh Ramachandran, CPA
Chief Accounting Officer
Chief Accounting Officer
209.10K
+207300.00%
Dr. Shankar Musunuri, Ph.D.
Dr. Shankar Musunuri, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Uday B. Kompella, Ph.D.
Dr. Uday B. Kompella, Ph.D.
Independent Director
Independent Director
--
--
Ms. Kirsten Castillo
Ms. Kirsten Castillo
Independent Director
Independent Director
--
--
Ms. Tiffany Hamilton
Ms. Tiffany Hamilton
Head of Communications
Head of Communications
--
--
Dr. Huma Qamar, M.D.
Dr. Huma Qamar, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Junge Zhang, Ph.D.
Mr. Junge Zhang, Ph.D.
Independent Director
Independent Director
1.17M
+117.00%
Dr. Arun Upadhyay, Ph.D.
Dr. Arun Upadhyay, Ph.D.
Chief Scientific Officer, Head of Research and Development
Chief Scientific Officer, Head of Research and Development
214.50K
+153362.00%
Mr. Ramesh Ramachandran, CPA
Mr. Ramesh Ramachandran, CPA
Chief Accounting Officer
Chief Accounting Officer
209.10K
+207300.00%
Dr. Shankar Musunuri, Ph.D.
Dr. Shankar Musunuri, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Uday B. Kompella, Ph.D.
Dr. Uday B. Kompella, Ph.D.
Independent Director
Independent Director
--
--
Ms. Kirsten Castillo
Ms. Kirsten Castillo
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2023
FY2021
FY2020
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
1.75M
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Jan 18
Updated: Sun, Jan 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Janus Henderson Investors
6.10%
The Vanguard Group, Inc.
5.02%
UBS Financial Services, Inc.
1.43%
Musunuri (Shankar Ph.D)
1.36%
Millennium Management LLC
1.27%
Other
84.82%
Shareholders
Shareholders
Proportion
Janus Henderson Investors
6.10%
The Vanguard Group, Inc.
5.02%
UBS Financial Services, Inc.
1.43%
Musunuri (Shankar Ph.D)
1.36%
Millennium Management LLC
1.27%
Other
84.82%
Shareholder Types
Shareholders
Proportion
Investment Advisor
9.45%
Investment Advisor/Hedge Fund
8.28%
Hedge Fund
3.73%
Individual Investor
2.09%
Research Firm
0.47%
Corporation
0.35%
Venture Capital
0.14%
Bank and Trust
0.05%
Other
75.44%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
260
72.72M
22.18%
+8.84M
2025Q3
255
51.36M
16.44%
-32.04M
2025Q2
268
78.45M
26.84%
-13.23M
2025Q1
278
81.07M
27.89%
-11.63M
2024Q4
292
76.62M
26.34%
-21.25M
2024Q3
306
84.66M
29.43%
-6.14M
2024Q2
300
72.04M
27.84%
+19.28M
2024Q1
302
36.88M
14.47%
-15.26M
2023Q4
300
30.54M
12.06%
-31.79M
2023Q3
314
37.28M
14.69%
-34.75M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Janus Henderson Investors
20.00M
6.4%
+19.70M
+6514.39%
Nov 28, 2025
The Vanguard Group, Inc.
15.22M
4.87%
+450.90K
+3.05%
Sep 30, 2025
UBS Financial Services, Inc.
841.04K
0.27%
+438.31K
+108.83%
Sep 30, 2025
Musunuri (Shankar Ph.D)
1.34M
0.46%
+607.32K
+82.50%
Apr 14, 2025
Millennium Management LLC
4.16M
1.33%
-896.78K
-17.73%
Sep 30, 2025
GMT Capital Corp.
4.15M
1.33%
--
--
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
3.83M
1.23%
-1.36M
-26.19%
Sep 30, 2025
Geode Capital Management, L.L.C.
3.68M
1.18%
+189.39K
+5.43%
Sep 30, 2025
Citadel Advisors LLC
1.57M
0.5%
+966.20K
+160.49%
Sep 30, 2025
State Street Investment Management (US)
1.36M
0.43%
+16.46K
+1.23%
Sep 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
Invesco NASDAQ Future Gen 200 ETF
0.82%
Pacer WealthShield ETF
0%
iShares Russell 2000 ETF
0%
iShares Micro-Cap ETF
0%
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Russell 2000 Growth ETF
0%
Global X Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
View more
Invesco NASDAQ Future Gen 200 ETF
Proportion0.82%
Pacer WealthShield ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
iShares Micro-Cap ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
